New Analyst Forecast: $SEPN Given $18.0 Price Target - Nasdaq
4 weeks ago • Google News
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflamm.